RxDoctor Payments Data

Jennifer Helker, APRN

Psychiatric/Mental Health · Liberal, KSNPI 1326690496

Payments from drug & device makers

$1,303in general payments, 2019–2025

Across 74 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$262
  • Ironshore Pharmaceuticals Inc.$192
  • E.r. Squibb & Sons, L.L.C.$167
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
  • Supernus Pharmaceuticals, Inc.$107
  • Alkermes, Inc.$82
  • plus $332 from 7 others

What the payments were for

  • Food & beverage$1,303100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,303 in reported general payments places this provider in the 65th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$11,871
Medicare patients
65
Services billed
137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate41$126,330
Invega TrinzaPaliperidone Palmitate13$119,226
AristadaAripiprazole Lauroxil11$34,606
UzedyRisperidone11$29,168
CaplytaLumateperone Tosylate16$24,113
VraylarCariprazine Hcl16$22,599
RexultiBrexpiprazole13$20,161
Aripiprazole72$12,474
Duloxetine Hcl124$3,338
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$2,783
Atomoxetine Hcl15$2,651
Divalproex Sodium71$2,557
Chlorpromazine Hcl14$2,248
Divalproex Sodium ErDivalproex Sodium35$2,045
Olanzapine130$1,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$71$245,55654 claims
Alkermes, Inc.Aristada$82$34,60611 claims
Teva Pharmaceuticals USA, Inc.Uzedy$42$29,16811 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$160$24,11316 claims
AbbVieVraylar$262$22,59916 claims
Otsuka America Pharmaceutical, Inc.Rexulti$60$20,16113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Liberal

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →